Page 53 - Hospital Authority Annual Report 2016-2017

Hospital Authority Annual Report 醫院管理局年報 2016-2017

Strategic intent: 策略目標：
Ensure service quality and safety 確保服務質素及安全

HA continued to adopt modern technology and new treatment 醫管局繼續引入現代科技與新治療方法，
options, including the use of new biomarkers to improve the 包括採用引導性更高的生物標記技術，協
accuracy of prostate cancer detection. We also built up service 助診斷前列腺癌。我們亦於瑪麗醫院提供
capacity of In-vitro Fertilisation (IVF) by adding IVF cycles in 額外人工受孕治療周期以加強人工受孕服
Queen Mary Hospital. For prevention of hepatitis B reactivation 務。另為預防癌症病人復發乙型肝炎，我
for cancer patients, additional hepatitis B virus DNA tests were 們為目標病人提供額外乙型肝炎基因測試。
provided for target patients.

The scope of HA Drug Formulary was widened to cover more 醫管局擴大《醫管局藥物名冊（》藥物名冊）
drugs with accumulated scientific evidence on clinical efficacy. Two 以涵蓋更多具實證療效的藥物，包括將兩
classes of self-financed drugs for secondary stroke management 類治療中風及骨質疏鬆的自費藥物納入為
and osteoporosis treatment were repositioned as special drugs 名冊專用藥物，並放寬三種治療糖尿病、
in the HA Drug Formulary, while the clinical applications of 預防骨質疏鬆性骨折及治療乳癌專用藥物
three special drug classes were expanded for management of 的臨床應用。為提高藥物名冊的透明度，
diabetes mellitus, secondary prevention of osteoporotic fracture 醫 管 局 推 出《醫 管 局 藥 物 名 冊 管 理 手 冊 》
and breast cancer treatment. As a proactive measure to enhance （手冊），重點載列藥物名冊的管治架構、
the transparency on the Drug Formulary, the HA Drug Formulary 原則、運作程序、諮詢機制及持份者的參
Management Manual (“the Manual”) was published, with 與。我們向各持份者介紹手冊內容，加深
particular emphasis on the governance, principles, operating 他們對藥物名冊的了解和信心。
procedures, consultation and engagement of stakeholders in HA’s
drug formulary management. HA promulgated the Manual to its
stakeholders to enhance their understanding and confidence in
HA’s drug formulary management system.

51